GTC featured in the Orange County Business Journal on February 3, 2020
Genomic Testing Cooperative (GTC) and C2i Genomics Announce Collaboration to Offer Liquid Biopsy Testing for Staging and Monitoring Solid Tumors Based on Pattern Recognition of Whole Genome DNA Signature IRVINE, Calif. and NEW YORK, Jan. 14, 2020 /PRNewswire/ — Genomic Testing Cooperative, LCA (GTC), a cooperative (Co-Op) company offering comprehensive genomic profiling of hematologic and solid tumors, and C2i Genomics, Inc, a tumor pattern recognition liquid biopsy company, today announced collaboration to develop liquid biopsy tests for the staging and monitoring of solid tumors. C2i Genomics approach is based on proprietary technology using AI-based pattern recognition of whole genome sequencing of cell-free DNA (cfDNA). The technology will be adapted by GTC […]
GTC Solid Tumor Profile™ with 434 genes test is now covered by Medicare for patients with a wide range of solid tumor cancers Irvine, California– January 7, 2020 – Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has established coverage for its solid tumor molecular profile. The GTC-Solid Tumor Profile provides a comprehensive evaluation of the abnormalities in the entire coding sequence of 434 genes in various types of solid tumors. This decision of covering solid tumors along with the previous coverage decision of two GTC hematology profiles allows GTC to offer comprehensive genomic profiling with next-generation sequencing (NGS) for patients with all types of […]
Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting Irvine, California– December 3, 2019 – Genomic Testing Cooperative, LCA (GTC) announced that they will be presenting data on their proprietary AI-based algorithms and RNA and DNA testing at the American Association of Hematology (ASH) annual meeting. In collaboration with multiple academic centers, GTC developed new approaches for the classification of diseases and prediction of response to combination therapy. Dr. Maher Albitar, GTC Chief Executive Officer and Chief Medical Officer, stated “Cancer is complex disease and requires complex biomarkers for predicting its behavior. RNA Sequencing provides a wealth […]
GTC featured in the Orange County Business Journal on September 30, 2019 [Click image to enlarge]
![Time Matters on Health Tests [TAT-NGS]](https://genomictestingcooperative.com/wp-content/uploads/cache/images/Record-Breaking-TAT-Turn-Around-Time-NGS-Next-Generation-Sequencing-/Record-Breaking-TAT-Turn-Around-Time-NGS-Next-Generation-Sequencing--3202049713.jpg)
We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay leads to a worse outcome Patients with cancer who have to wait longer for treatment suffer from significant anxiety and stress Physicians and patients deserve to get the results of a diagnostic test, with the shortest possible turnaround time (TAT) When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible. Are you waiting 21-28 days to receive your NGS results? Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 7 days of […]
MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions must be distinguished from MDS. While dysplasia in hematologic cells is an indication of the diagnosis of MDS, the presence of mutations along with cytopenia is the most conclusive evidence for the diagnosis of MDS. Normal individuals above the age of 50 may show mutation in some genes (ASXL1, TET2, DNMT3, and TP53), however, the level (Variant allele frequency, VAF) […]
GTC Receives Medicare Coverage for 2 NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms Irvine, California– June 19, 2019 – Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has finalized its review and has established coverage for two Genomic Testing Cooperative (GTC) hematology profiles: GTC-Hematology (177 gene DNA profiling) and GTC-Hematology Plus (177 gene DNA and 1408 gene RNA profiling). The two Comprehensive Genomic Profile (CGP) tests are designed to help Pathologists and Hematologists/Oncologists in establishing the precise diagnosis, prognosis and determine therapy in hematologic neoplasms. The GTC Hematology test (177 gene DNA Profile) can be performed on cell-free DNA (cf-DNA) from […]
When you order GTC Breast Cancer Profile The FDA has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. FDA approval of the drug was based on detecting one of 11 frequent mutations in PIK3CA. Based on our data, these 11 mutations constitute only 62.83% of the mutation we detect when Next Generation Sequencing (NGS) is used. Abnormalities in PIK3CA have been reported in approximately 30% of patients with breast cancer. […]
The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities and that has progressed during or following prior platinum-containing chemotherapy. Urothelial tumors have been reported to show abnormalities in FGFR3 (22%), FGFR1 (8%), and FGFR2 (2%). These abnormalities involve mutations, fusion and amplification/overexpression. Abnormalities in FGFR can also be seen in various tumor types including lung (20%), breast (10%), melanoma (20%) rhabdomyosarcoma (7%), and cervical cancer (5%). Genomic Testing Cooperative (GTC) offers comprehensive testing of FGFR(1, 2, 3, and 4) covering mutations in all coding sequence, various fusions and expression levels. However, mutations studied in […]
